Skip to main content

Intermediate Grade Lung Neuroendocrine Neoplasm clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    open to eligible people ages 18 years and up

    This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

    San Francisco, California and other locations

Last updated: